Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $115

Benzinga Newsdesk www.benzinga.com Positive 84.0%

Neg 0% Neu 0% Pos 84%

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $102 to $115.